RE:RE:RE:RE:RE:RE:RE:SigilonObviously RS are not disastrous for EVERY stock. It would be for this stock because there are lots of large legacy shareholders who have very little faith left in management and a RS would be the last straw, me being one of them. You can see what would happen by the reaction to your question on this board. That should be reason enough. No one thinks it's be positive besides you so that should answer your question. There is no shortage of sellers as it is and this will only compound. As someone said, sva has way too much baggage and reverse split is a bandaid solution to get uplisted. The reason it's not at the minimum list price is because of poor management decisions and lack of communication. No informed investor is sitting around waiting to buy sva only if it gets listed on the Nasdaq. They'll know it was just rolled back to get there and likely will be delisted in short order because the company can't get a flow of news out like they've been promising for literally years. You think the magical news fairies are going to spring into action once listed? The problem here is lack of important investor communication. All of the info they present everyone knows. Did anyone learn anything from the last 2 presentations? When was the last time you learned something? They need to put out an news release detailing your pharma partners and what they are using the pouch for. Put out news releases of the plan getting hemo into the clinic with timelines. Same for thyroid. They need to cater to the sophisticated investors looking for value by being sophisticated. Not paying for coverage by media outlets no one knows about or cares about or reads. They need to step their game up if they want to be taken seriously. I don't think Phil is the right guy to do it. All the money they spend on useless stuff, why not hire someone to do the presentations who can actually captivate an audience. Phil should be spending his time in the lab not answering amateur investor questions and doing promotional presentations. You don't need to be making half a million a year to do presentations. Lots of positive stuff happening with this company but management really needs to lose the cheap venture suit and slip into something more classy and play the part of big Pharma If they want to be taken seriously.